Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Myriad Genetics (MYGN) PT Lowered to $19 at Jefferies
February 7, 2020 9:14 AM ESTJefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $19.00 (from $23.00) while maintaining a Hold rating.
The analyst commented, "We expect MYGN to open sharply lower (down >20% after-hours) after another 2Q miss, ~50% cut to '20 EPS guide & abrupt CEO... More
Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
February 6, 2020 4:13 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.23, $0.08 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $209.81 million.
GUIDANCE:
Myriad Genetics sees Q3 2020 EPS of $0.02, versus the consensus of $0.30. Myriad... More



